Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, R&D spend, and cash-runway figures in Arcutis Biotherapeutics (ARQT) SEC documents can stretch across hundreds of pages. If you need to know how ZORYVE sales offset development costs or where the next PDE4 program stands, wading through every quarterly update is time-consuming and complex.
Stock Titan solves this problem with AI-powered summaries that turn raw disclosures into plain-English takeaways. Whether you are searching for “Arcutis quarterly earnings report 10-Q filing,” want “Arcutis insider trading Form 4 transactions,” or need an “Arcutis proxy statement executive compensation” breakdown, our engine surfaces the exact paragraph in seconds. Real-time alerts appear the moment an “Arcutis Form 4 insider transactions real-time” notice hits EDGAR, while cross-links let you compare each metric historically for quick “Arcutis earnings report filing analysis.”
Dive deeper without the jargon: jump straight to liquidity tables in the “Arcutis annual report 10-K simplified,” scan risk-factor changes, or review pivotal Phase 3 data inside an “Arcutis 8-K material events explained” filing. Many professionals rely on us for “understanding Arcutis SEC documents with AI” because our platform highlights option-exercise patterns under “Arcutis executive stock transactions Form 4,” flags non-recurring charges, and maps clinical timelines to projected market launches. With comprehensive coverage of every 10-K, 10-Q, 8-K, S-1, and Form 4, plus clear explanations, complex immuno-dermatology disclosures finally make sense.
Arcutis Biotherapeutics (ARQT) reported a profitable Q3 2025 driven by strong product sales. Total revenue reached $99,219,000, more than doubling from $44,755,000 a year ago, and operating income was $8,526,000. Net income was $7,410,000, a sharp turnaround from a net loss of $41,537,000 in Q3 2024. Product revenue was led by ZORYVE foam at $49,781,000, ZORYVE cream 0.3% at $30,491,000, and ZORYVE cream 0.15% at $18,947,000. Cost of sales was $8,685,000.
For the first nine months, revenue was $246,569,000 versus $125,182,000 in 2024, with a net loss of $33,536,000. Cash, cash equivalents, restricted cash, and marketable securities were $191,068,000 as of September 30, 2025. The company reported long-term debt of $100,000,000 and interest expense of $3,071,000 for the quarter. Shares outstanding were 122,492,192 as of October 22, 2025. Management notes recent approvals across multiple ZORYVE formulations in the U.S. and Canada, and recorded a $10,000,000 milestone payment to AstraZeneca tied to sales, increasing intangible assets amortized through cost of sales.
Jennison Associates LLC reported beneficial ownership of 12,254,119 shares of Arcutis Biotherapeutics, Inc. common stock, representing
Larry Todd Edwards, EVP Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), reported sales of 4,504 shares of common stock on
Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported insider sales executed under a 10b5-1 plan adopted on June 3, 2025 with a plan end date of September 30, 2026. The Form 4 discloses three sale transactions on October 1-2, 2025: 15,000 shares at a weighted average price of $18.9135, 9,261 shares at $20.0164, and 20,739 shares at $20.0383, totaling 45,000 shares sold. Following the last reported sale the Form shows 846,440 shares held directly by the reporting person. The filing notes multiple indirect holdings held in trusts and an LLC and includes undertakings to provide detailed per-trade price information on request.
Arcutis Biotherapeutics (ARQT): Director Howard G. Welgus reported Form 4 transactions on 10/01/2025. He exercised 9,538 stock options at $1.6806 per share and sold 9,538 shares at a weighted average price of $18.9227, plus an additional 462 shares at $18.9227. Following these trades, he directly owned 99,744 shares.
The transactions were effected under a Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. The reported option was fully vested and carries an expiration date of 03/13/2029.
Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a proposed sale of 20,739 common shares through Merrill Lynch with an aggregate market value of $415,574, planned for 10/02/2025. The shares were acquired on 03/01/2025 via restricted stock vesting. The filing lists 119,905,078 shares outstanding for the company, which provides context for the relative size of the sale. The filer, identified in past-sales records as Todd Franklin Watanabe, sold a total of 45,937 shares in the prior three months for gross proceeds of $812,132 across four transactions dated 08/04/2025, 09/08/2025, 09/09/2025, and 10/01/2025. The filer certifies they are not aware of undisclosed material adverse information.
Arcutis Biotherapeutics (ARQT) insider filing reports a proposed sale of 24,261 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $469,074 and an approximate sale date of 10/01/2025. The shares reflect restricted stock vesting events on 03/01/2025 (6,255 shares), 05/01/2025 (3,988 shares) and 08/01/2025 (14,018 shares). The filer also reported three recent sales within the past three months: 504 shares on 09/09/2025 for $8,829, 9,625 shares on 09/08/2025 for $168,800, and 11,547 shares on 08/04/2025 for $165,429.
Form 144 filing for Arcutis Biotherapeutics (ARQT) shows a proposed sale of 10,000 common shares planned for 10/01/2025 through Merrill, with an aggregate market value of $189,227. The issuer has 119,905,078 shares outstanding. The seller's holdings were acquired mostly through stock option exercise and restricted stock vesting between 2018 and 2023, totaling several thousand shares per grant. The filing also discloses two recent sales by the same person: 10,000 shares sold on 09/02/2025 for $156,383 and 10,000 on 08/01/2025 for $142,982. The signer certifies no undisclosed material adverse information.
Todd Franklin Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported planned sales of company common stock under a 10b5-1 trading plan. On 09/08/2025 he sold 9,625 shares at a weighted average price of $17.5376, leaving 891,944 shares reported as directly beneficially owned after that transaction. On 09/09/2025 he sold 504 shares at a weighted average price of $17.5179, leaving 891,440 shares reported as directly beneficially owned after that transaction. The 10b5-1 plan was adopted on June 14, 2024 and has a stated end date of September 30, 2025. The filing also reports indirect holdings: 25,410 shares held by The John Franklin Watanabe Trust, 25,410 shares held by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares held by Watanabe Ventures, LLC, and 124,956 shares held by The Watanabe 2016 Irrevocable Trust. The Form 4 was signed by an attorney-in-fact on 09/10/2025.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
